Healthcare Startups funded by Y Combinator (YC) 2024

Ginkgo Bioworks is the organism company. We design custom organisms for customers across multiple markets. We build our foundries to scale the process of organism engineering using software and hardware automation. Organism engineers at Ginkgo learn from nature to develop new organisms that replace technology with biology.

Notable Labs is building a personalized drug discovery platform to identify treatment options for relapsed and refractory cancer patients — starting with blood cancer — to address the long tail of cancer treatment. We look at a person’s actual cancer cells, test combinations of FDA approved drugs, and see which combinations kill the cancer cells and leave the healthy cells alive. We focus on combinations because cancer is often difficult to target with just one drug and starting with a single drug can lead to resistant clones or relapse. We're building a highly automated lab in Foster City running on our custom software and are currently testing relapsed/refractory cancer patients as well as samples from a variety of pharma/biotech partnerships. https://www.notablelabs.com/careers

We make oral drugs to treat and prevent viral infections - like COVID-19.

Diassess Inc. is revolutionizing the way infectious diseases are prevented, diagnosed, and monitored by developing the tools necessary to empower people to become knowledgeable about their health. We produce inexpensive, disposable health diagnostic hardware that transforms any smartphone into a portable, real-time health-monitoring device for rapid, accessible, multiplexed analysis of bodily fluids anywhere in the world.

Solugen is decarbonizing the chemistry of everyday life with enzymes and innovative metal catalysts. Our new to the world Bioforge platform technology can produce high value chemical goods that are biobased and carbon negative, at cost on par with current technologies. We are making sustainable chemistry accessible to all living things, to ensure a prosperous world exists for generations.

Today, biologists spend too much time pipetting by hand. We think biologists should have robots to do pipetting for them. People doing science should be free of tedious benchwork and repetitive stress injuries. They should be able to spend their time designing experiments and analyzing data. That's why we started Opentrons. We make robots for biologists. Our mission is to provide the scientific community with a common platform to easily share protocols and reproduce each other's results. Our robots automate experiments that would otherwise be done by hand, allowing our community to spend more time pursuing answers to some of the 21st century’s most important questions.

Our API-connected healthcare infrastructure empowers our partners to deliver world-class patient experiences. We power prescribing, lab testing and pharmacy fulfillment.

At Athelas, we're bringing simple, life-changing health care products to people around the globe. The future of healthcare is at the home - we are a team of technologists building the next generation of medical products at the intersection of hardware and software. We won’t stop until we’ve brought the world class tools of a hospital to your home. Athelas Remote Patient Monitoring (RPM) allows healthcare providers to monitor patient vitals like blood pressure, weight, and blood glucose without the patient ever having to enter a clinic, improving patient health and engagement, and reducing hospitalizations. We do this all through a beautifully integrated suite of devices and software tools that provides access to state-of-the-art technologies and groundbreaking AI powered analysis.

We enable people to live their best lives. As we succeed, there is more convenience, healthier communities and thriving businesses. We get medications to those who need them and improve information, access and management of their care and enable businesses to move online and gain access to consumers who need their services

Papa is a one-stop-shop for flexible family care, providing companionship and a helping hand wherever it’s needed. With wide-ranging industry, technology, and transformation experience, we share a vision for a world where no one has to go it alone. And a deep well of gratitude for the Papa People who move this vision forward. Founded in 2017 and headquartered in Miami, Papa is backed by Canaan, Tiger Global Management, Comcast Ventures, SoftBank Vision Fund 2, TCG, Initialized Capital, and Seven Seven Six, among other revered institutional and individual investors. Papa is an equal opportunity employer. We proudly support the ParityPledge® for gender and/or racial parity at the highest levels of business.

Clipboard Health exists to lift as many people up the socioeconomic ladder as possible. We dramatically improve lives by letting healthcare professionals turn extra time and ambition into career growth and financial opportunity. We achieve this with our app-based marketplace that connects healthcare facilities and healthcare professionals, allowing healthcare professionals to book on-demand shifts and healthcare facilities to access on-demand talent. Our mission is to enable healthcare professionals to work when and where they want and to enable healthcare facilities to meet their talent needs. Clipboard Health is a fast-growing Series C startup with classic two-sided network effects. We have product-market fit, generate substantial revenue, and we are helping nurses fix healthcare one shift at a time. Clipboard Health is a diverse and inclusive company with a global, remote-first team of hundreds of people. We’ve been featured on YC’s Top Companies and grown our revenue 25x in the last 18 months. We need your help to keep growing so we can serve more healthcare professionals, healthcare facilities, and patients.

Modern Health is the leading mental wellness platform that combines clinically validated assessments, personalized stress management support, an international network of certified behavioral health coaches, and licensed therapists to deliver mental health support across a broad range of individual needs. Modern Health empowers employers to lead the charge in helping their employees be less stressed, more engaged, and happier through evidence-based technology and professional support. Modern Health has raised over $170M from top investors Battery Ventures, Kleiner Perkins, Founders Fund, and John Doerr and supports over 200 companies globally including Lyft, Pixar, SoFi, Credit Karma, Electronic Arts, Cooley, and Okta.

BillionToOne has developed a DNA molecular counter that increases the cell-free DNA diagnostics resolution by over 1,000 fold, which unlocks transformative improvements in prenatal screening and liquid biopsy for cancers. Unity Screen, BillionToOne's commercially available non-invasive prenatal test (NIPT), is the only NIPT that can assess fetal risk for both recessive conditions and aneuploidies from maternal blood. UNITY Screen continues to grow exponentially and is on its path to becoming the next standard-of-care, with an increasing number of publications showing its accuracy and advantages over other screening methods. We have also recently used our molecular counting technology to develop liquid biopsy tests, which have the potential to completely transform oncology care.

H1 helps connect the healthcare ecosystem by providing a global platform of every healthcare professional and healthcare organization.

SmartSpot is a post Series-A stealth startup backed by Founders Fund and Khosla Ventures that uses computer vision to deliver an unparalleled fitness training experience to your home. Our unique hardware solution gives amazing trainers the ability to see their class participants in real time and deliver detailed advice that was previously only possible in person.

CareRev is a technology platform empowering healthcare professionals to take control of their careers. CareRev provides a direct line between healthcare facilities and local clinical talent, cutting out the middleman and enabling professionals to work where and when they want. Together, we’re building the local, resilient, flexible healthcare workforce of the future. For more information, visit carerev.com or follow us on LinkedIn.

Memora Health helps healthcare organizations digitize and automate complex care workflows, making them simple for patients and clinicians to navigate. Memora ingests existing data on clinical workflows, converts them into cohesive messaging journeys that guide patients through their care episodes, and automates the completion of simple follow-up tasks in the EMR. Memora's platform reduces care team notifications by nearly 40%, has a >70 average NPS, and has improved clinical outcomes across various populations. Contact us at info@memorahealth.com

Atomwise is a preclinical tech-enabled biotech using machine learning for hit discovery, hit expansion, and lead optimization. We were the first team to apply convolutional neural networks to drug discovery. We focus on identifying and optimizing novel small molecule scaffolds and unlocking previously-undrugged protein targets.

Healthcare needs good data. At PicnicHealth, we are building deep real-world datasets fueling cutting-edge research while giving patients control of their own medical record data. These complete, clinically-rich datasets produce unique insights — across dozens of diseases — to ultimately get the right treatments into patients’ hands faster. We work directly with patients and leverage state of the art machine learning to transform messy medical records into structured, research-ready datasets. To date we’ve helped tens of thousands of patients securely access their records and proactively contribute to advancing research in diseases that impacts their lives.

Out-of-pocket healthcare costs are skyrocketing and every day, people all across America are forced to make difficult decisions about their health. Lively is the benefits solutions provider that gets it right. We designed our solutions to take the guesswork out of managing benefits. And our innovative features are built to simplify benefits administration and evolve with your business. Managing wellness and wealth takes more than a series of transactions. By combining robust features with unparalleled service, we make benefits administration effortless, even when time and energy are limited. Experience benefits administration as it should be with Lively. Go to www.livelyme.com to learn about how HSAs other modern employee benefits can help you and your team.

Asher Bio is a biotechnology company developing precisely targeted immunotherapies for cancer and other diseases. Our cis-targeting platform aims to enable selective activation of specific immune cell types, addressing the inherent limitations of otherwise pleiotropic immunotherapies that act on multiple cell types. Our approach has the potential to precisely direct different immune mediators against a range of target immune cell-types and create best-in-class immunotherapies in cancer, autoimmune and infectious diseases. Asher Bio is backed by Third Rock Ventures and is located in South San Francisco.

Ribbon Health is a health care data platform that provides the critical infrastructure that health insurers, medical providers, and digital health solutions need to enable accurate provider directories, reliable referral management, and efficient care navigation. We offer a seamless API layer that integrates into each health care organization's existing workflow to build connectivity across the industry and continuously improve the accuracy of its data with its spread and use. Ribbon is the only solution to offer all of these capabilities in one platform, and delivers the most comprehensive data on doctors, insurance plans, and the cost and quality of care culled from thousands of sources. By providing this infrastructure, Ribbon delivers on its mission of making it easy for every health care decision to be high-quality, cost effective, and convenient.

Ophelia helps people quit opioids without going to rehab. We offer online doctor’s visits, withdrawal medication prescriptions, and support for long-term recovery, using a protocol 6x more effective than most rehabs (2/3rds of which don't have doctors). More than 3 million Americans are addicted to opioids, but 80% are not getting help, due to jobs, families, and privacy concerns. Meanwhile, there's a proven treatment that increases survival rates by 600%, and it's low cost, discreet, and convenient. It's called MAT, and it looks like treatment for anxiety or depression: medication plus therapy. However, doctors need a special waiver to prescribe the medication, which fewer than 5% of them have, so it's difficult to get, and most people are buying it on the street. Sadly, drug dealers aren't doctors: every 11 minutes another American dies of an opioid overdose, now the #1 cause of death for Americans under 50. Ophelia is replacing rehab with telemedicine, using proven science and a consumer-first approach. The opioid treatment market in the U.S. is $15B, and 85% of opioid addicts have insurance that pays for it. We're treating roughly 400 patients with thousands more waiting. Zack started Ophelia after losing his girlfriend to an opioid overdose, who found it easier to get medication from a drug dealer than a doctor. We are raising money to help patients in waiting, grow our footprint, save lives, and earn venture-level returns for investors.

Culture Biosciences grows cells for biotech companies. Our customers genetically modify organisms to produce new therapeutics, materials, fuels and foods. We help them quickly run experiments and develop manufacturing processes so they can get their products to market faster. We've built proprietary software and automation systems to make operating our bioreactors more efficient than existing systems. We also provide customers with new software tools that help them analyze and contextualize their data. We are currently serving a number of biotech customers and scaling out our infrastructure.

Pelago, formerly Quit Genius, is the world’s leading virtual clinic for substance use management. We are transforming substance use support—from prevention to treatment—delivering education, management skills, and opportunities for positive change to members struggling with substance use, most commonly tobacco, alcohol, or opioids. Our solution gives employers the means to offer on-demand, personalized support to workers seeking to live healthier lives. Pelago’s cognitive behavioral therapy (CBT) and medication-assisted treatment (MAT) programs deliver convenient, accessible, and effective support that seamlessly integrates with health plans, pharmacy benefit managers, and wellness platforms. To date, Pelago has helped more than 750,000 members manage their substance use and improve their lives.

Nurx is a telemedicine startup focused on increasing access to healthcare, starting with birth control and PrEP services.

Verge uses artificial intelligence and human data to develop better drugs faster. Verge has an end-to-end technology-driven drug discovery and development platform, featuring one of the field’s largest and most comprehensive proprietary patient genomics datasets from human tissue. Verge uses machine learning to mine this data and develops these insights into new drugs using it’s human-centric biology and chemistry platforms.

Qventus’ mission is to simplify how healthcare operates so it just works — for everyone. The company offers an AI-based software platform that helps hospital teams make better operational decisions in real-time. Qventus addresses operational challenges across the hospital including emergency departments, perioperative areas, patient safety, in-patient, outpatient and pharmacy. Located in Silicon Valley, Qventus is honored to be working with leading public, academic and community hospitals across the United States. Founded in 2012, Qventus was named among Fast Company’s Most Innovative Companies for 2018. The company has also been recognized as a leader and innovator in operational excellence, with the 2016 Fierce Innovations Award in Healthcare and Healthcare Informatics 2017 Innovator Award. For more information about Qventus, please visit www.qventus.com

Reliance Health uses technology to make quality healthcare delightful, affordable and accessible in emerging markets. Through an integrated approach that includes affordable health insurance, telemedicine and a combination of partner and proprietary healthcare facilities, Reliance Health offers innovative healthcare solutions that meet the needs of emerging markets including Nigeria, Egypt and growing

Endpoint Health is on a mission to address urgent needs in immune-driven critical and chronic illnesses by delivering therapies that are personalized to each patient’s biology. We built Endpoint Health from the ground up to develop and commercialize therapeutics and therapy-guiding tests, to ensure that every patient receives personalized treatment that will dramatically improve their outcomes. Our vision is a world in which all patients have effective, personalized treatment, because therapies are targeted to the right patient at the right time.

Curebase is reinventing decentralized clinical trials to help the vast majority of potential patients that currently cannot access clinical research. Curebase’s vision is that any patient, no matter where they are located, should be able to participate in clinical trials at home and with their own doctors. This is made possible through a unique suite of tools, including all-in-one eClinical software and virtual research sites, designed to engage patients in clinical trials across all settings, be it at home, at their local clinic, or other places in their community.

Redcliffe Labs (a unit of Redcliffe Lifetech Inc) provides diagnostics with a comprehensive portfolio approach both with routine and specialised test menus with advanced testing labs all over India. Its digital first approach with on-demand 1-hour home collection and same day report is disrupting the way diagnostics is delivered today and thus is the fastest growing in India. Redcliffe Labs is providing 3500+ tests across its wide network of labs and collection centres. The company has served about millions of Indians and is processing more than 250K+ test parameters daily. The test portfolio is very wide including routine pathology tests, advanced genetic screening, research-based DNA tests in reproductive health, cancer and wellness/fitness. The easy to interpret smart reports provide key health check-points, which can help in diagnosing and treating both chronic and acute diseases on time. Redcliffe Labs has pioneered Drone technology adoption in the diagnostic sector by opening up the first commercial corridor from Uttarkashi to Dehradun. The company currently has 30+ labs and 700+ authorised collection centres in more than 120 cities across India. Redcliffe's vision is to provide world-class diagnostic services to people across the Indian sub-continent in an affordable manner.

Ansa Biotechnologies is developing a new way to make DNA that will be faster, cleaner, and more accurate than existing methods. Currently, DNA is manufactured via a chemical method that has remained mostly unchanged for 35 years. Our enzyme-based approach promises to dramatically accelerate innovation in biological research and biotechnology, including therapeutics, diagnostics and biomanufacturing.

We're a women’s health company making personalized reproductive health information more accessible, earlier in life. We make the same laboratory tests that were previously confined to fertility clinics more accessible for women at home. By arming women with powerful information about their reproductive health, Modern Fertility is closing the fertility information gap and enabling women to own the decisions impacting their bodies and futures. We've raised $22 million from Forerunner Ventures, Maveron, Union Square Ventures, First Round Capital, #Angels and Y Combinator.

Osmind is the premier platform for clinicians and researchers advancing new life-saving mental health treatments. Today, mental health disorders are one of the leading causes of death worldwide, especially among young adults, and are tied to shortening lifespans. While there have been developments in new psychiatric medications since the first FDA approval in 1954, today there is a growing movement among clinicians, patients, and researchers who are recognizing the need to accelerate new science. The Osmind treatment platform is the first and only solution that solves specific challenges faced by neuropsychiatric clinics, spanning general psychiatry and interventional psychiatry (transcranial magnetic stimulation, ketamine, SPRAVATO®, psychedelic medicine, electroconvulsive therapy). The core electronic health record (EHR) technology is precisely developed for interventional treatment workflows and designed to support a strong therapeutic alliance, including journaling tools and assistance with health plan reimbursement, which is a significant access hurdle for millions of patients. Research from our platform is already helping to set new standards for mental health interventions. For example, in the largest published real-world analysis of ketamine infusion therapy for depression, we teamed up with Stanford University School of Medicine to share findings in the Journal of Affective Disorders (March 2022). We have multiple ongoing research studies leveraging our proprietary real-world data, including an even larger ketamine analysis leveraging machine learning to predict treatment outcomes. Osmind is a San Francisco–based public benefit corporation led by scientists, technologists, and psychiatrists. We are backed by top investors including DFJ Growth, General Catalyst, Future Ventures, Tiger Global, and Y Combinator.

Gilgamesh is a pioneering, clinical stage mental health science-focused biotechnology company. We have a disciplined focus on developing innovative new chemical entities (NCEs) leveraging a unique combination of medicinal chemistry, intellectual property strategy, neuroscience & neurobiology, and drug development expertise. We are an experienced team, with proven success in biotech exits and inventions.

64x Bio is building a platform that radically increases the speed and scale of mammalian cell line discovery. Using a novel high throughput discovery and screening platform and an integrated computational design loop, we are developing new ways of generating highly optimized and otherwise unattainable cell lines for the manufacturing of viral vectors, with a specific focus on those used for cell and gene therapies. Our platform technology enables pharmaceutical and biotechnology companies to bring cell and gene therapies to patients more effectively, providing purpose-built genetically engineered cell lines to increase the efficiency of viral vector production and reduce the cost of manufacturing.

DrChrono develops the essential platform and services for modern medical practices to make care more informed, more interactive, and more personalized. The open platform powers telehealth, electronic health record (EHR), practice management, medical billing, and revenue cycle solutions for physicians and patients, and is fully extensible via a robust API and marketplace of applications and services. The platform is used by thousands of physicians and millions of patients, and is facilitating millions of patient appointments and is processing billions of dollars in medical billing. For more information about DrChrono, visit www.drchrono.com

Meru Health is an online provider for greater mental health with remote clinicians (licensed therapists & psychiatrists), a smartphone-based treatment program, a biofeedback wearable and an anonymous peer-support group. Meru Health is committed to evidence-based care and has published groundbreaking clinical outcomes in several peer-reviewed medical journals with Harvard & UC Davis. Meru Health has offices in San Mateo CA, Denver CO and Helsinki, Finland.

We're a primary care practice that helps residents of senior living communities lead healthier, happy lives. Our mission is to keep senior living residents healthy—by keeping them away from hospitals where exposure to health risks is high. Through our new clinical care delivery model, we bring clinicians right into senior living communities, providing safer, more convenient primary care. Pine Park partners with senior living communities to provide primary care to their residents, building a value-based care model where we keep patients healthier. This allows us to provide comprehensive healthcare on-site, see patients regularly, and better support their holistic health.

Science Exchange powers R&D outsourcing for the world’s top life sciences companies. Our marketplace gives scientists access to the innovation and research they need and our platform fully automates R&D outsourcing from source to pay so scientists can focus on what they love—science.

**TL;DR:** Legacy (YC S19) is a startup focused on the fast-growing field of fertility and family planning. Founded at Harvard, the company has now raised almost $50M from leading investors like FirstMark Capital, Bain Capital Ventures, Section 32, Tribe Capital, and even celebrities like Justin Bieber, The Weeknd, and others. For context, we've closed 4 venture rounds in 2.5 years, in addition to our celebrity round of funding. **What we're doing** We are building a complete digital health hub for future fathers/parents. We aim to change the outdated view that fertility is a "women's issue" by creating an accessible, affordable product for men & people with sperm. This includes everything from a mail-in kit for sperm testing & sperm freezing, personalized sperm improvement products, tele-health, DNA fragmentation analysis, supplements, and more. **Why are we the leader?** The company was founded at Harvard by a team of healthcare and fertility experts. We obsess about talent density and have out-executed our competitors over the past few years. Beyond our D2C channel, we've also unlocked: 1. Insurance (We cover over 10M individuals through insurance in NY and CA) 2. Military (We serve the Navy SEALs & other SpecOps through exclusive programs) 3. Employers (We work with the top fertility benefit providers like Progyny, Carrot, and Maven) **Tell me about the team** We're a team of under 50, extremely diverse (majority female, majority immigrants, strong LGBQTIA+ representation, age range of 25-65), and very values driven. Our 5 values are customer centricity, reliability, kindness, openness, and winning. Learn more about our values here: https://khaled-legacy.medium.com/legacys-values-and-why-they-matter-db116539d3da Learn more about our workplace here: https://khaled-legacy.medium.com/how-and-why-legacy-is-reinventing-workplace-benefits-9e5fda6cb863 Read about our mission to humanize the path to parenthood: https://khaled-legacy.medium.com/how-and-why-legacy-is-reinventing-workplace-benefits-9e5fda6cb863 Learn more about sperm and why it matters here: docsend.com/view/zkgk7ws

Blueberry Medical provides concierge pediatric care with at-home medical diagnostics and an always-available team of Pediatricians. Blueberry handles twice as may illnesses as any other telemedicine provider and has proven to reduce ER costs by 50%.

Parallel Bio created a human 'immune system in a dish' to discover drugs and immunotherapies more likely to work in patients. Our platform has all of the same elements as a human immune system, meaning you can test drugs and vaccines as if you were testing them in actual patients from the start. The biggest reason why 95% of new drugs fail is that they were tested in mice - but with our human platform, pharma companies will know which drugs will successfully treat patients, speeding up the process and reducing the cost. To date our platform has successfully been used to test 12 drugs, and vaccines against 8 different diseases. The company is founded by Robert DiFazio, a former Stanford R&D director with a PhD in immunology, and Juliana Hilliard, a former System1 Biosciences R&D lead with an MSc in bioengineering, both of whom have led drug discovery programs for years.

We're a SaaS company with emphasis on Service, and we have a mission: to improve the happiness of scientists and the quality of their research. HappiLabs provides a service called the Virtual Lab Manager. We offer PhD level, former scientists to help with safety and regulatory, product research, lab shopping, negotiating, purchasing, inventory, and bookkeeping. Our software tools, such as the ETA Dashboard and the HappiApp, make it easy to request purchases, manage inventory, and check-in packages upon delivery. HappiLabs also has one of the most extensive databases of product prices. These tools, and experienced humans, make us the smartest lab managers in the world. Another way to think of us is an outsourced purchasing department and/or a personal assistant for your scientists. Based in Chicago, and some presence in San Francisco. If you're a newly funded PI, a startup, small biotech, or work with purchasing as a big pharma/biotech, you can use our help.

Scanbase makes it easy for medical companies to convert photos of rapid diagnostic tests into results. We do this by providing a simple API that any medical company can access.

If we've learned anything in the last few years it's that spending time with our friends and family is essential to our well-being and happiness. Unfortunately, loud and noisy places like weddings and family gatherings hinder human connection, especially for the hearing impaired. In fact, the biggest unmet need in the entire hearing healthcare industry is hearing in noisy places. AudioFocus helps patients hear in these environments by only enhancing voices nearby the patients and ignoring ones farther away. We do this using acoustics informed machine learning and custom microphone array design. Our goal is to increase the adoption rate of 37M US adults with hearing loss, only 8M use hearing aids today. Founded by Auditory Neuroscientist & AI expert and a Hearing Aid hardware design expert.

We develop novel therapeutics for globally relevant, diseases of high unmet medical need, by targeting the transcriptome.

Chronic pelvic pain is a debilitating condition, that impacts over 15 million US women and costs over $39 Billion each year to manage. V-Flow medical has developed a trio of products that target the root cause of chronic pelvic pain, allowing millions of women to avoid opioid use and restart living a normal, pain free life. The V-Flow team has successfully scaled, multiple start-up medical device companies in various clinical disciplines with a combined exit value of over $4B. We have developed a broad IP portfolio covering both device design and method of application. A recent landscaping identified no competing IP for our indication of use. We have tested our beta prototypes and are initiating animal models ahead of a planned first in human investigation in Q1 2023. Following discussion with the NIH program advisors, we have been encouraged to apply for a phase 1 grant, call to action for the Heal initiative to find new diagnostic and non-drug treatments for chronic pelvic pain.

Subscription model pharmacy for patients with chronic diseases in Latin America. We delivery medicine every month and help with the insurance reimbursement. We're currently operating in Mexico.

India’s insurance market is filled with bygone products, which do not cater to 95% of the market's demand for specific products such as illness-specific insurance, primary care with insurance, and surgical insurance to name a few. We, at IMT, aim to target this white space by creating innovative products that fulfill this new demand by empowering the agents. Agents are the largest insurance distribution channel in India and cover 85% of the premium collection. Agents collect 20B premium every year. With a 5% take rate, it’s a 1B dollar market opportunity growing at 22% CAGR. Kunal has 15+ years of experience working with insurance companies and building agent networks, while he scaled his brokerage business to 3M dollars in revenue. Rachit has 12+ years of experience in building tech products, he was a founding engineer at Payu (stripe of India).

Formerly known as Patchd Medical Wearable technology and AI to predict and prevent sepsis outside of hospital.

Kivo Health provides telehealth rehab for chronic lung disease patients. We offer an 8-week clinical program led by a live therapist, which saves payers $6,000 per patient. Only 3% of eligible patients are getting this life-changing therapy right now.

Kernal Bio creates mRNA 2.0 therapies that instruct specific cells on how to make their own medicine. Kernal Bio encrypts mRNA’s “message” in a language that only cancer cells understand. These tumor-specific mRNA therapeutics allow precise targeting of cancer cells, without harming normal cells or tissues. They have recently been validated in preclinical tumor models, showing high efficacy and safety as well as durable adaptive immunity. With roots at MIT, Harvard and Biopharma, Kernal’s management team has deep expertise in mRNA therapeutics space. CEO Yusuf Erkul, M.D., M.B.A. is a successful drug hunter whose research at Merck enabled an FDA-approved drug for ovarian cancer. President, Burak Yilmaz, M.S., previously founded Sentegen, a thriving synthetic biology company which commercializes synthetic DNA, RNA, and diagnostic kits for genetic and infectious diseases. VP of BD, Matt Strout, M.D. Ph.D., M.B.A, is a business development executive who led more than $4.5B worth of BD deals at Alexion and AstraZeneca. VP of R&D Manfred is a leader in immuno-oncology, who was most recently Scientific Senior Director at Bristol-Myers Squibb (BMS).

ReleviumBio is developing an injectable gel for knee osteoarthritis. Approximately half the population will be diagnosed with this pain and progressive disease. Right now, patients have to undergo not only repeat injections to control their pain, but also have to take strong oral medications. Because the disease is progressive and only gets worse over time, many patients end up on highly addictive, high-dose opioids. To date, we have secured $3.7 million in non dilutive funding and completed preclinical testing. We demonstrated that our drug is safe, selectively blocks nerves that transmit pain, and provides pain relief that lasts four times as long. My co-founder and I are Chemists with PhDs in Biomedical Engineering and we have an experienced leadership team already in place. Insurance currently pays $770 per six-monthly treatment for knee osteoarthritis. With 5 million patients in the US, this represents a $7.7 Bn market opportunity. This platform biotherapeutic can also be used to treat other joints affects by osteoarthritis such as the hip and ankle, where the same problems exist in treatment care.

Metriport helps healthcare organizations access and manage comprehensive patient medical data. Through a single integration, Metriport ensures clinical accuracy and completeness of medical information to providers, delivering comprehensive consolidated patient clinical data at the point-of-care. By standardizing, de-duplicating, consolidating, and hydrating the data with medical code crosswalking, providers get a rich understanding of their patients' medical histories through Metriport. Metriport is the only open-source solution of its kind that offers all these integrations in a single platform, and standardizes complex data formats into industry standards such as FHIR and C-CDA. As a developer-first, HIPAA and SOC 2 Type II compliant interoperability solution, Metriport is powering the next wave of innovators in healthcare, creating an internet for healthcare data.

Liv Labs is a consumer healthtech company making modern solutions for incontinence. 29 million American women worry about leaking pee in public: an $8B market. Liv Labs is developing convenient self-care versions of proven-effective clinical treatments, including adaptive health coaching software and a novel continence pessary. Device inventor, Carly Price, reimagined the humble pillow for Casper and now leads digital retail design at Walmart. Company CEO, Melody Roberts, incubated digital service experiences now scaling globally at McDonald’s and Panera. We’ve raised $2.6M, including NIH and NSF grants, based on stellar effectiveness data and user feedback like, “With this, surgery is off the table.” US, European and Hong Kong utility patents have issued; Australia will soon. Our FDA-reviewed clinical trial launched at Northwestern University and continues at the OSU and UAB.

Current Description: RTHM provides virtual-first care for complex illness including Long COVID, ME/CFS, POTS, and mast cell activation. Many clinics focus on teaching patients how to better cope with symptoms, which is helpful, but we don’t stop there. We develop collaborations & partnerships so our patients access to the most promising testing and root-cause directed early therapies for their illness(es) with the goal of simplifying and streamlining the most efficient and effective clinical pathways so they can be scaled in the form of low cost online modules overseen remotely by clinicians. In conjunction with clinical care, RTHM operates a clinical lab and collects deep molecular data with robust clinical context to develop AI-powered diagnostics and better ways of predicting which treatments may work best for whom.

We are Pulse Active Stations Network and are setting up a network of connected IOT-enabled “Make in India” Smart Health Machines known as the Pulse Active Stations Network. We have conducted over 600,000 Health Check-ups and through our Pulse Active Station Smart Health Machines, we conduct mass screening for NCD risk factors such as Obesity, Hypertension and other factors to empower people to take informed decisions for theirs and their family's health.

BIOS Health was previously called Cambridge Bio-Augmentation Systems (CBAS) and focused on prosthetic neural interfaces as a first market. Now we use

Kips Health enables physical therapists to automatically collect RTM reimbursements with only 5 minutes of work.

We’re building the AI copilot for radiologists, powered by a foundational model for medical imaging. RadMate AI will read radiology images and generate full reports for radiologists to review and submit. Mohamed and Adam are technical co-founders who met while studying Computer Science at Cornell University. Before starting RadMate AI to solve the problems his dad faced as a radiologist, Adam worked at Palantir on the initial launch of Palantir’s Al Platform. Mohamed has experience at AWS, where his goal was to help enterprises innovate on the cloud, and PathAl, where he worked on their image viewer platform to improve the workflow of pathologists.

Float brings a nurse to your home when you’re sick. If you have a chronic illness, instead of making you come to an overcrowded hospital full of sick people, we bring the best of the hospital to you.

We are solving clinician staffing shortages for hospitals by automating routine patient-facing tasks.

Helping pregnant parents save the most personal source of stem cells - from their umbilical cord and placenta - to unlock future disease treatments. Offering cord blood banking, cord tissue banking, and placenta stem cell banking.

Ruth Health treats the 83% of post-pregnancy womxn who pee in their pants. We deliver 30-minute Postpartum Recovery + Training Sessions via telehealth, so moms around the globe with pelvic floor prolapse can get back to work, sex, and normal life—5x faster. Using conversational AI + biometric readings, Ruth Health will accumulate the largest, most diverse database in America on longitudinal maternal health

We go to nursing homes, and we put an internet-connected bed sensor underneath all their beds. Our app gives nurses valuable insights and an overview of all their residents. We reduce fall incidents and bedsores while improving evening and night shift productivity by over 30%. Momo Medical solves the biggest problem affecting nursing homes, staff shortages while increasing the quality of care.

Loula is a software platform and national provider network for independent birth & postpartum doulas who accept Medicaid/Medi-Cal. Doulas typically operate outside of the traditional healthcare system and face an enormous learning curve and administrative burden when trying to accept insurance. This is why we created Loula. Starting with doulas in California, Loula handles their credentialing, contracting, and revenue cycle management so that they can focus on delivering the best quality care to their clients.

Arpeggio Bio is a pioneering pharmaceutical company that develops drugs targeting transcription factors using AI and high-throughput RNA-sequencing. With $20M in venture funding, we've targeted "undruggable" proteins like NRF2, TEAD, and GPX4 where our lead program is rapidly progressing towards a DC for the treatment of IO-resistant melanoma. With partnerships with J&J and FORMA, we've validated our platform in rare disease and inflammation with a significant Phase I success.

MentalHappy is a tele-health platform that allows health professionals to facilitate online support groups.The MentalHappy app allows health professionals to facilitate online support groups to help meet the rising demand for mental health services, create meaningful impact and earn extra revenue. Some groups are more intimate, while others have 100+ members, spanning different life events from grief support, healing from illness, life after divorce, black mental health, LGBTQIA+, stress management, emotional fertility support, coping with anxiety, and many other groups.

Fortuna Genomics employs methods from revolutionary genomics studies to non-invasively assess embryo traits, enabling parents to optimize their children's innate qualities without the need for gene editing. Through comprehensive genetic screening and forecasting, it empowers families to make informed decisions, optimizing their child’s well-being and capabilities from conception. With the convergence of advancements in genomic technologies, association studies, and sequencing efficiency, we are at a unique inflection point where such services can become widely accessible and impactful. Accurately predicting complex traits from genetic markers involves sophisticated models that must account for the interplay between countless biological and statistical factors. Our team is well-equipped to tackle this problem and make every parent's dream a reality by allowing them to give their children the best possible start in life.

Auricle is a medical device company building a breakthrough neurostimulation implant to restore hearing in millions of patients who no longer benefit from hearing aids, get less than 60% on a word recognition test, but aren't prepared to make the jump to a cochlear implant. Our approach preserves remaining natural hearing through a reversible and less invasive surgery, addressing the key concerns that hold most patients back from getting a cochlear implant (currently the only treatment option for these patients). The company spun out of Stanford Biodesign having completed two acute human clinical studies demonstrating the approach will work. The team is now focused on developing their full implant system for their first clinical trial. Auricle addresses a currently unserved profile of hearing loss that affects a growing population of 3.5 million patients in the US and represents an immediately accessible $1.2B market opportunity with existing reimbursement.

In the global fight against breast cancer, Digistain stands at the forefront, offering a beacon of hope to millions. Our journey began at Imperial College London, where ground-breaking research gave birth to a technology poised to revolutionize breast cancer diagnostics. The Challenge: Every year, breast cancer affects 2.3 million individuals globally. Post-surgery, 60% of patients are advised to undergo genomic testing, an expensive and time-consuming process monopolized by a single lab in the U.S., costing around $4,000 and taking nearly two months. Consequently, only 5% undergo this vital testing. The rest, unable to access this crucial diagnostic step, often resort to chemotherapy—a treatment that, in one in four cases, is more harmful than the cancer itself. Our Solution: Digistain addresses this critical gap. Our technology transforms the current diagnostic process by enabling hospitals to analyze patient samples in-house using existing equipment, supplemented with our innovative technology. This approach offers near-instantaneous decision-making data, a stark contrast to the existing month-long waits. Central to our technology is a proprietary algorithm that identifies a unique spectral fingerprint of the tumour in the infrared spectrum, providing a personalized risk score. This score guides oncologists in selecting the most effective, individualized treatment plans, potentially reducing unnecessary chemotherapy and its harmful side effects. Impact and Potential: Our solution not only challenges the status quo in technology but also in accessibility. In a landmark government-commissioned study, Digistain demonstrated clinical evidence on par with the market leader, but at a fraction of the cost and time. Already making waves in clinical practice globally, with insurance reimbursement at leading cancer centers, our technology represents a paradigm shift in cancer care. Recognized by the Institute of Physics, the Royal Society, and Imperial College for our innovative contributions, and supported by entities like the NHS, Y Combinator, and the European Investment Bank, Digistain is more than a company—it’s a movement towards equitable, effective cancer treatment. With the potential to democratize access to life-saving diagnostics, Digistain is not just envisioning a better future for cancer patients; we are actively creating it.

Keylika is an early stage biopharma startup developing metal-based drugs using a platform synthesis technology to treat unmet medical needs. We then administer these drugs using proven delivery technologies to effect the best clinical outcomes. Our first product is a small molecule iron drug (new molecular entity) delivered by a wearable skin patch to treat Iron Deficiency Anemia (IDA), with significantly higher safety, efficacy and tolerability over existing treatments. This is poised to be a best-in-class, potentially breakthrough therapy for treating iron deficiency without any GI side-effects (eg. nausea, constipation, diarrhoea, etc.) typically associated with oral iron supplements, and without the risks, costs and side-effects associated with IV iron infusions. When approved, Keylika’s proprietary transdermal iron will be the world's first prescription iron patch. Iron deficiency is a hugely understated problem affecting about 1.6 billion people worldwide and more than 30 million in the US alone, translating to a $17B US market.

38 million people suffer from heart rhythm disorders and are recommended to start medications that can save their lives, but require rigorous ECG monitoring to start and remain on these pills. SafeBeat Rx moves beyond diagnostics to guide these therapeutics, powered by our ML ECG software that integrates with existing FDA-cleared wearables to allow seamless physician approval of drug dosing, all from a mobile phone. We are a team of physicians, engineers, data scientists, and machine learning experts dedicated to using engineering to improve heart health.

At Diffuse Bio we’re building a push-button entirely AI software platform for molecular design, leveraging breakthroughs in generative AI. Our team has been behind breakthroughs in AI protein design for the past 6 years, including the first experimental validation of AI-generated proteins and diffusion models for protein structure and sequence.

Mederva Health helps hospitals & doctors in developing countries provide better care for their patients by tapping into the best US medical experts. Doctors abroad use our web app to consult with and learn from our board-certified physicians, like cardiologists and oncologists from Stanford, Harvard, and Johns Hopkins.

Humane Genomics has developed a platform to engineer cancer killing viruses. We have taken a first principles approach to design and make oncolytic viral therapies. Using a highly lytic RNA virus engineered with "2 factor authentication" (using selective infection and selective replication) they have an on-target to off-target kill ratio > 1000. We are working on our first indication, pediatric liver cancer (hepatoblastoma), with our partners at Texas Children's Hospital, who are world leading experts. We have in vivo (mouse) data showing safety and currently developing efficacy data and are showing 50% reduction in tumor volume.

Probably Genetic is changing the lives of patients living with severe, complex diseases. Our data platform is used by drug developers and patient advocacy groups to develop and launch treatments for these patients. Our technology discovers undiagnosed patients online, analyzes their disease state using machine learning and at-home testing, and enables compliant communication with patients. In doing so, we help patients access diagnoses, clinical trials, and treatments as early as possible.

Isabl has developed software that can analyze the entire genome of cancer patients. Today, when people get cancer, they get a genetic test of their tumor that analyzes only a few possible mutations. With Isabl, you run the tumor through an Illumina sequencer and get the whole genome, then our software is able to analyze all the mutations. Our breakthrough technology provides unprecedented clarity into tumor biology to aid treatment planning. This opens up opportunities for precision diagnostics, disease surveillance and biomarker discovery.

Sigma Genetics develops devices that can deliver DNA, RNA, and other charged molecules into cells by using magnetic fields. When compared to conventional electroporation, this technique has several key advantages, which include: the absence of arcing, the ability to scale, and the benefit of being non-invasive for in vivo applications. This platform technology can be applied to a wide range of applications- cell therapies, cancer drug delivery, DNA vaccines, biopharma manufacturing, and cosmetics.

Sixfold is focused on the commercialisation of its patented drug delivery systems for RNA therapeutics such as siRNAs for gene silencing and mRNAs for gene expression.

We're building autonomous robots to make surgery more consistent, error free, and efficient. Nick is a 3x founder from medtech who co-founded a $1 billion company. Kartik is a 3x founder from autonomous vehicles who built and launched the world's first driverless truck. Surgical robotics companies are worth ~$200 billion total. AI will dominate the next generation of surgical robotics and we will be the first to build it. We're starting with a common urologic procedure that has by far the best outcomes but is not widely adopted due to technical difficulty.

Rebellyous Foods is a food manufacturing technology and production company defined solely to catapult meat alternative production toward price parity with animal-based meat. Rebellyous implements novel food manufacturing equipment and processes in large-scale production to produce low-cost plant-based meat at high volumes. These goals are achieved through uniquely designed food products, the use of high-throughput manufacturing automation and ‘smart’ production centers, and the development and utilization of new innovative low-energy manufacturing tools. Working closely with industry partners, Rebellyous makes plant-based meat sustainable, affordable, and widely available.

Vision Disease cause innumerable cases of preventable blindness globally - 415 million diabetic patients worldwide are susceptible to Diabetic Retinopathy (DR), Glaucoma, and more. Current screening protocols for vision disease require ophthalmologists to manually diagnose patients through visual assessment of the fundus. Given the large number of diabetes patients in various communities, this process is expensive, inefficient, and an undue burden on eye clinics.

Dear Brightly offers prescription skin products online. Our mission is to get people access to the most effective, dermatologist vetted skincare products for healthy skin, using technology.

X-ZELL™ is a global start-up specialising in rare cell detection technology. Backed by Y Combinator and various high-profile angel investors from around the globe – among them Gmail creator Paul Buchheit – X-ZELL™ has developed a world-first platform technology capable of isolating and visualizing rare and abnormal cells such as Circulating Endothelial Cells (CEC). X-ZELL™’s platform technology is based on four core modules covering the entire spectrum from blood processing through to cell analysis and reporting – with every step performed in-house using patented and proprietary technology. By combining the wisdom of 4,000 years of pathologic research with X-ZELL™’s own, cutting-edge technology, X-ZELL™ ensures robust results and maximum clinical utility across a broad range of medical applications – from research through to medication management, companions diagnostics, relapse control and diagnostic decision-making. More information on www.x-zell.com and @XZELLInc

We are building a platform of bacterial molecules to awaken our body’s innate ability to control inflammation and heal. Our first indication is Crohn’s Disease, which affects over 500,000 Americans at an annual cost of $10B. After Crohn's disease, we are going for type 1 Diabetes and Multiple Sclerosis.

Delivery of TERT mRNA extends telomeres sufficiently in a few days to reverse over a decade of telomere shortening during normal aging. We are advancing TERT mRNA-based therapies to the clinic.

TrueClaim processes all payments between healthcare providers and companies that self-fund their insurance. Unlike incumbents, TrueClaim uses newly available data and AI to save companies 7% of their healthcare costs.